US2017119829A1PendingUtilityA1

Method for inducing production of vascular endothelial growth factor

59
Assignee: TANABE TADASHIPriority: Aug 31, 2009Filed: Jan 11, 2017Published: May 4, 2017
Est. expiryAug 31, 2029(~3.1 yrs left)· nominal 20-yr term from priority
Inventors:Tadashi TanabeKeiichi HukudaTakashi Kawakami
A61K 38/52A61K 38/1866A61P 43/00A61K 48/005A61K 38/1825A61K 35/13A61P 35/00A61K 38/1833A61P 9/00A61P 9/10C12Y 503/99004A61K 45/06C12N 2799/025A61K 35/76A61P 7/02C12N 2750/14132A61K 31/5585C12N 2750/14143A61P 9/08C12N 7/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF). The method includes administering, to an individual, a composition including adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) which synthesizes prostaglandin

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for inducing production of vascular endothelial growth factor (VEGF), the method comprising: administering, to an individual, a composition comprising an adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) which synthesizes prostaglandin I 2  (PGI 2 ). 
     
     
         2 . The method according to  claim 1 , wherein the AAV is of a type selected from the group consisting of type 1, 2, 5 and 8 
     
     
         3 . The method according to  claim 1 , wherein the AAV is of a type selected from the group consisting of type 1 and 2. 
     
     
         4 . The method according to  claim 1 , wherein the AAV induces one or more activities selected from the group containing of vasodilation, anti-platelet aggregation and angiogenesis. 
     
     
         5 . The method according to  claim 1 , wherein the composition further comprises a pharmaceutically permissible carrier containing the AAV, the carrier being selected from the group consisting of water, a water-propylene glycol mixed solution, a buffered solution, and 0.4% saline. 
     
     
         6 . The method according to  claim 1 , wherein the AAV further carries a second gene coding for an angiogenesis factor selected from the group consisting of genes coding for vascular endothelial growth factor (VEGF) and VEGF-2. 
     
     
         7 . The method according to  claim 6 , wherein the second gene coding for an angiogenesis factor is a VEGF. 
     
     
         8 . The method according to  claim 6 , wherein the AAV induces one or more activities selected from the group containing of vasodilation, anti-platelet aggregation and angiogenesis. 
     
     
         9 . The method according to  claim 6 , wherein the composition further comprises a pharmaceutically permissible carrier containing the AAV, the carrier being selected from the group consisting of water, a water-propylene glycol mixed solution, a buffered solution, and 0.4% saline.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.